Kevin Sundquist1, Bernard P Chang2, Faith Parsons1, Nathan Dalrymple1, Donald Edmondson1, Jennifer A Sumner3. 1. Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY 10032, United States. 2. Department of Emergency Medicine, Columbia University Medical Center, New York, NY 10032, United States. 3. Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY 10032, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, United States. Electronic address: js4456@cumc.columbia.edu.
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD) and depression are common after evaluation for suspected acute coronary syndrome (ACS), and are associated with poor prognosis. However, it is unclear whether patients discharged after suspected ACS access treatments for subsequent psychological distress. We examined self-reported rates of receiving psychotherapy and/or medication for psychological distress in patients one month after a suspected ACS event. METHODS: A sample of 448 adults (age 60.4±12.5; 47.8% female; 52.7% Hispanic, 32.1% Black) presenting to the emergency department with suspected ACS were recruited for the REactions to Acute Care and Hospitalization (REACH) study, an ongoing cohort study of medical and psychological outcomes after ACS evaluation. Socio-demographics and depressive symptoms were assessed in-hospital, and PTSD symptoms related to the suspected ACS event were queried via phone one month after enrollment. Participants also indicated whether they received either medication or counseling to deal with their emotions and coping after their heart problem. RESULTS: Approximately 15% (n=68) of the sample reported receiving some form of treatment. Treatment rate did not differ significantly as a function of demographics, ACS status, or insurance coverage, ps>0.1. Over a quarter of participants (25.3%) who screened positive for PTSD and/or depression reported receiving treatment. Participants with PTSD and depression had a higher treatment rate (47.6%) vs. those with only depression (12.8%) or PTSD (30%) or no psychopathology (10.3%). CONCLUSION: Findings suggest that 1 in 4 patients who screened positive for PTSD and/or depression reported receiving counseling or medication in the first month after a suspected ACS event.
OBJECTIVE:Posttraumatic stress disorder (PTSD) and depression are common after evaluation for suspected acute coronary syndrome (ACS), and are associated with poor prognosis. However, it is unclear whether patients discharged after suspected ACS access treatments for subsequent psychological distress. We examined self-reported rates of receiving psychotherapy and/or medication for psychological distress in patients one month after a suspected ACS event. METHODS: A sample of 448 adults (age 60.4±12.5; 47.8% female; 52.7% Hispanic, 32.1% Black) presenting to the emergency department with suspected ACS were recruited for the REactions to Acute Care and Hospitalization (REACH) study, an ongoing cohort study of medical and psychological outcomes after ACS evaluation. Socio-demographics and depressive symptoms were assessed in-hospital, and PTSD symptoms related to the suspected ACS event were queried via phone one month after enrollment. Participants also indicated whether they received either medication or counseling to deal with their emotions and coping after their heart problem. RESULTS: Approximately 15% (n=68) of the sample reported receiving some form of treatment. Treatment rate did not differ significantly as a function of demographics, ACS status, or insurance coverage, ps>0.1. Over a quarter of participants (25.3%) who screened positive for PTSD and/or depression reported receiving treatment. Participants with PTSD and depression had a higher treatment rate (47.6%) vs. those with only depression (12.8%) or PTSD (30%) or no psychopathology (10.3%). CONCLUSION: Findings suggest that 1 in 4 patients who screened positive for PTSD and/or depression reported receiving counseling or medication in the first month after a suspected ACS event.
Authors: Joost P van Melle; Peter de Jonge; Titia A Spijkerman; Jan G P Tijssen; Johan Ormel; Dirk J van Veldhuisen; Rob H S van den Brink; Maarten P van den Berg Journal: Psychosom Med Date: 2004 Nov-Dec Impact factor: 4.312
Authors: Jeff C Huffman; Felicia A Smith; Mark A Blais; Marguerite E Beiser; James L Januzzi; Gregory L Fricchione Journal: Am J Cardiol Date: 2006-06-12 Impact factor: 2.778
Authors: Kenneth E Freedland; Michael W Rich; Judith A Skala; Robert M Carney; Victor G Dávila-Román; Allan S Jaffe Journal: Psychosom Med Date: 2003 Jan-Feb Impact factor: 4.312
Authors: Jennifer A Sumner; Ian M Kronish; Robert H Pietrzak; Daichi Shimbo; Jonathan A Shaffer; Faith E Parsons; Donald Edmondson Journal: J Affect Disord Date: 2015-07-29 Impact factor: 4.839
Authors: Donald Edmondson; Safiya Richardson; Louise Falzon; Karina W Davidson; Mary Alice Mills; Yuval Neria Journal: PLoS One Date: 2012-06-20 Impact factor: 3.240
Authors: Donald Edmondson; Safiya Richardson; Jennifer K Fausett; Louise Falzon; Virginia J Howard; Ian M Kronish Journal: PLoS One Date: 2013-06-19 Impact factor: 3.240
Authors: Steven D Shapiro; Amelia K Boehme; Bernard P Chang; Eliza C Miller; Joshua Willey; Mitchell S V Elkind Journal: Neurohospitalist Date: 2020-11-05